Immune to Cancer: The CRI Blog
-
AACR 2022 Recap: T Cells Still On Top, But Make Room for Myeloid Cells
At the 2022 AACR annual meeting, CRI scientists highlighted a wide scope of cancer immunology advances, and…
-
AACR 2022 Preview: Decoding Cancer Complexity, Integrating Science, and Transforming Patient Outcomes
During AACR’s upcoming 2022 annual meeting, CRI scientists will share the latest advances in cancer immunotherapy.
-
ASCO21 Recap: Immunotherapy’s Continued Progress and Addressing Healthcare Disparities
ASCO21 highlighted the latest immunotherapy advances in checkpoint inhibition and cell therapies, and addressed disparities in healthcare.
-
AACR21 Recap: CRI Scientists Highlight the Latest in ‘Discovery Science Driving Clinical Breakthroughs’
During AACR21, CRI scientists highlighted how improving our understanding of basic immune biology may enable improved immunotherapies…
-
ESMO20 Preview: Immunotherapy Updates at the ESMO Virtual Congress 2020
The latest results from a variety of immunotherapy trials will be revealed during the ESMO Virtual Congress…
-
CRI Speaks with Dr. Steven A. Rosenberg, Winner of the 2020 AACR-CRI Lloyd J. Old Award in Cancer Immunology
Dr. Steven A. Rosenberg receives the 2020 AACR-CRI Lloyd J. Old Award in Cancer Immunology on June…
-
Recapping ASCO20: The Next Horizons in Immunotherapy
The 56th Annual ASCO Meeting highlighted advances in checkpoint immunotherapy, cell-based immunotherapies, and bispecific antibodies.
-
ASCO20 Update: Considerations for Checkpoint Inhibitors Moving Forward
Results unveiled at ASCO20 increased our understanding of checkpoint immunotherapy in a variety of cancers and circumstances.
-
ASCO20 Update: Cellular Immunotherapies, Genomics, and COVID-19
Several promising cellular immunotherapies were discussed at ASCO20, including those for solid cancers; plus updates on the cancer…